News Daily News Can’t Exercise for a Cardiac Stress Test? That’s a Bad Sign Todd Neale February 25, 2025
News Daily News Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA Michael O'Riordan February 24, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Aortic Stenosis Slowed by SGLT2 Inhibitors in Observational Study Yael L. Maxwell February 20, 2025
News Daily News More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin L.A. McKeown February 14, 2025
News Daily News Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE Yael L. Maxwell February 14, 2025
News Daily News Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time Michael O'Riordan February 13, 2025
News Conference News THT 2025 Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity Todd Neale February 12, 2025
Presentation THT 2025 When and Why Are Diuretics Sometimes Just Not Enough? Presenter: Jennifer Cowger February 12, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025
News Daily News Use of Secondary CVD Prevention Meds Still Meager Worldwide Caitlin E. Cox February 03, 2025
News Daily News Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations L.A. McKeown January 31, 2025
News Industry News Genomadix Inc. Announces Health Canada License for Rapid Genetic Test to Aid Therapy Selection for Stroke and Cardiovascular Disease Patients January 30, 2025
News Daily News Aspirin Use for Primary Prevention Declining in US: NHANES Michael O'Riordan January 24, 2025
News Daily News Societies Update Appropriate Use Criteria for Cardiac Implantable Devices Todd Neale January 23, 2025
News Daily News Ischemic vs Bleeding Risks: Do Antiplatelet Guidelines Need Rethinking? Yael L. Maxwell January 23, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025